Zobrazeno 1 - 10
of 1 543
pro vyhledávání: '"EGFR-TKIs"'
Autor:
Shanshan Huang, Yaling Long, Yuan Gao, Wanling Lin, Lei Wang, Jizong Jiang, Xun Yuan, Yuan Chen, Peng Zhang, Qian Chu
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-14 (2024)
Abstract Background Aberrant activation of mesenchymal epithelial transition (MET) has been considered to mediate primary and acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small ce
Externí odkaz:
https://doaj.org/article/072706ab2ba84703ae0b7712ea79cc75
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-15 (2024)
Abstract This systematic review and network meta-analysis evaluates first-line treatment options for patients with EGFR-mutant non-small cell lung cancer (NSCLC) and brain metastases. We analyzed 24 randomized controlled trials (RCTs) involving 2,682
Externí odkaz:
https://doaj.org/article/8ebe442c00564a6bbb358712a3a844c2
Publikováno v:
Zhongguo quanke yixue, Vol 27, Iss 35, Pp 4426-4434 (2024)
Background Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are one of the individualized targeted therapeutic options for patients with advanced EGFR mutated non-small cell lung cancer (NSCLC), which can significantly improve
Externí odkaz:
https://doaj.org/article/f0f5d8cc5e5c42f68c4254095dc12849
Autor:
Jiali Wang, Xianhai He, Zhirong Jia, Aiwen Yan, Kang Xiao, Shuo Liu, Mengjun Hou, Yaling Long, Xuansheng Ding
Publikováno v:
Pharmaceutical Biology, Vol 62, Iss 1, Pp 33-41 (2024)
AbstractContext Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Gefitinib is a first-line treatment for NSCLC. However, its effectiveness is hindered by the development of drug resistance. At present, Shenqi Fuzheng injecti
Externí odkaz:
https://doaj.org/article/cdc0cd86e3184b7ab2c53f0fb2845907
Autor:
Qingsong Li, Na Liang, Weiwei Ouyang, Shengfa Su, Zhu Ma, Yichao Geng, Yinxiang Hu, Huiqin Li, Bing Lu
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Purpose The most appropriate time of primary tumor radiotherapy in non-small cell lung cancer(NSCLC) with EGFR-TKIs remains unclear. The aim of this study was to investigate the effect of the time factor of primary tumor radiotherapy on long
Externí odkaz:
https://doaj.org/article/11afa3d0e40b46c1b5b170451759b2c5
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-13 (2024)
Abstract Molecular targeted therapy resistance remains a major challenge in treating lung adenocarcinoma (LUAD). The resistance of Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs, epidermal growth factor receptor-tyrosine kinas
Externí odkaz:
https://doaj.org/article/82880fd7d7644e3c8d2b9ace73f79c30
Publikováno v:
Thoracic Cancer, Vol 15, Iss 23, Pp 1757-1763 (2024)
Abstract Background Epidermal growth factor receptor (EGFR) mutations are key drivers in a significant portion of non‐small‐cell lung cancer (NSCLC) patients. While third‐generation EGFR‐tyrosine kinase inhibitors (TKIs) such as osimertinib h
Externí odkaz:
https://doaj.org/article/a723a07ac722459eaa7b4f28f3ca4fe7
Autor:
Diao Yunlian, Huang Shibo, Liu Fangpeng, Liao Shu, Guan Chenxi, Xiong Xiaojian, Zhang Ping, Li Junyao, Zhang Wei, Ying Ying
Publikováno v:
Acta Biochimica et Biophysica Sinica, Vol 56, Pp 1549-1560 (2024)
Acquired resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs) represents a primary cause of treatment failure in non-small cell lung cancer (NSCLC) patients. Chemokine (C-C motif) ligand 2 (CCL2) is recently found to play a pivotal role in deter
Externí odkaz:
https://doaj.org/article/2104750fcc1545be8f0a691301454a65
Publikováno v:
Drug Design, Development and Therapy, Vol Volume 18, Pp 2571-2591 (2024)
Jun Shao,* Yunru Gu,* Renhua Guo, Jiali Xu Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China*These authors contributed equally to this workCorrespondence: Renhua Guo
Externí odkaz:
https://doaj.org/article/4cbeec78384b4a328def85f9a4794d4e
Autor:
Zhen Chen, Karin A. Vallega, Vijay K. Boda, Zihan Quan, Dongsheng Wang, Songqing Fan, Qiming Wang, Suresh S. Ramalingam, Wei Li, Shi‐Yong Sun
Publikováno v:
Advanced Science, Vol 11, Iss 35, Pp n/a-n/a (2024)
Abstract There is an urgent need to fully understand the biology of third generation EGFR‐tyrosine kinase inhibitors (EGFR‐TKIs), particularly osimertinib, and to develop mechanism‐driven strategies to manage their acquired resistance. Transien
Externí odkaz:
https://doaj.org/article/724fd6fccbf0485f8840bc5a1b713315